Safety

Gastrointestinal events remain the most frequently reported findings

Nausea, vomiting and constipation dominate reported adverse events, mostly mild to moderate and dose-escalation related.

Analysis

What this means

Full analysis for this development is in preparation. Published entries will set out what was reported, how it fits the existing evidence base, and what would need to change for the conclusion to shift.

Retatrutide Report does not provide dosing guidance, sourcing information or treatment recommendations. Coverage is limited to trial data, published literature and regulatory documents.

Category
Safety
Publication date
12 Aug 2026
Source
Published trial data